A PHASE 1/2 DOSE ESCALATION STUDY OF THE BCL-2 INHIBITOR ZN-d5 AND THE WEE1 INHIBITOR ZN-c3 IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA ZN-d5-004C

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Myleloid Leukemia
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    In order to participate in the study the following conditions must be met:
    1. Histologically or cytologically confirmed AML, as defined by World Health Organization (WHO) 2016 revised criteria (Döhner 2017), including secondary and therapy-relat

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. Known active CNS involvement (leukemic blasts in cerebrospinal fluid or imaging evidence of CNS disease).
    2. Diagnosis of acute promyelocytic leukemia.
    3. Any of the


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.